Statement: In total cohort 1 of the primary trial recorded more than 10 times the number of adverse events as cohort 2.
Primary_evidence: Adverse Events 1:   Total: 14/67 (20.90%)   Febrile neutropenia 21/67 (1.49%)   Leukopenia 21/67 (1.49%)   Neutropenia 21/67 (1.49%)   Macular hole 21/67 (1.49%)   Diarrhoea 22/67 (2.99%)   Abdominal pain 21/67 (1.49%)   Abdominal pain upper 21/67 (1.49%)   Enteritis 21/67 (1.49%)   Gastritis 21/67 (1.49%)   Nausea 21/67 (1.49%)   Vomiting 21/67 (1.49%)   Pneumonia 21/67 (1.49%) Adverse Events 2:   Total: 1/10 (10.00%)   Febrile neutropenia 20/10 (0.00%)   Leukopenia 20/10 (0.00%)   Neutropenia 20/10 (0.00%)   Macular hole 20/10 (0.00%)   Diarrhoea 20/10 (0.00%)   Abdominal pain 20/10 (0.00%)   Abdominal pain upper 20/10 (0.00%)   Enteritis 20/10 (0.00%)   Gastritis 20/10 (0.00%)   Nausea 20/10 (0.00%)   Vomiting 20/10 (0.00%)   Pneumonia 20/10 (0.00%)